Accelerating global antibacterial innovation

Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator (CARB-X) is a global non-profit partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria. With up to US$480 million to invest in 2016-22, CARB-X funds the best science from around the world. The CARB-X portfolio is the world’s largest early development pipeline of new antibiotics, vaccines, rapid diagnostics and other products to prevent, diagnose and treat life-threatening bacterial infections.

CARB-X is led by Boston University and is funded by the US Department of Health and Human Services Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response (ASPR), the Wellcome Trust, a global charity based in the UK working to improve health globally, Germany’s Federal Ministry of Education and Research (BMBF), the UK Government’s Global Antimicrobial Resistance Innovation Fund (UK GAMRIF), the Bill & Melinda Gates Foundation, the world’s largest foundation dedicated to improving the quality of life for individuals around the world, and receives in-kind support from National Institute of Allergy and Infectious Diseases (NIAID), part of the US National Institutes of Health (NIH). CARB-X headquarters are at Boston University School of Law.

Our vision

Life-saving innovation to keep the world prepared for dangerous bacterial infections.

Our mission

Accelerate a diverse portfolio of innovative antibacterial products towards clinical development and regulatory approval with funding, expert support and cross-project initiatives. We focus on the dangerous bacteria identified by the WHO and CDC priority lists.

How CARB-X works

In addition to non-dilutive funding, CARB-X provides scientific and business support to accelerate the development of products focused on the most serious drug-resistant bacteria identified by the WHO and CDC. The goal is to support them through the early stages of preclinical development and Phase 1 so they can attract private or public investment for further clinical stage development.

CARB-X is investing up to $480 million in 2016-2022 into the research and development of new antibiotics, vaccines, rapid diagnostics and other life-saving products to tackle the global threat of drug-resistant bacteria.

CARB-X was created in response to the US government’s 2015 Combating Antibiotic Resistant Bacteria (CARB) initiative, and the UK government’s call in 2016 for concerted global effort to address the growing drug-resistance public health crisis. CARB-X was launched July 28, 2016, by two divisions of the US Department of Health and Human Services (HHS): the Biomedical Advanced Research and Development Authority (BARDA), which is part of the Office of the Assistant Secretary for Preparedness and Response (ASPR) and the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH).

CARB-X is funded by BARDA, Wellcome Trust, Germany’s Federal Ministry of Education and Research (BMBF), the UK Government’s Department of Health and Social Care through its Global Antimicrobial Resistance Innovation Fund (GAMRIF), and the Bill & Melinda Gates Foundation. NIAID provides preclinical services to CARB-X-funded research projects. CARB-X is headquartered at the Boston University School of Law.

CARB-X’s Global Accelerator Network provides business, scientific and technical expertise and services to CARB-X-funded product developers to support their antibacterial research projects. The Network also plays a key role in addressing common challenges facing the antibacterial product development community.